PART I: Cancer Center Administration undertakes a range of activities essential to maximizing the effectiveness of CCSG-supported infrastructure and adding value to the UC Davis Comprehensive Cancer Center (UCDCCC) research enterprise and the integrated cancer program with the Lawrence Livermore National Laboratory (LLNL), submitted as consortium in this application. Administrative oversight of CCSG expenditures ensures that they are used only in the ways specified by NCI Guidelines and in the competitive renewal proposal for NCI designation. Activities encompass support for scientific programs and collaborations, membership coordination, Shared Resources (SR) oversight, developmental funds used for pilot studies, recruitment, and developing Shared Resources; clinical trial data management, collection of data for cancer related research funding, member publications and leadership activities. The Administration adds value to the cancer research effort by planning and organizing scientific meetings such as the weekly cancer biology seminars, the annual cancer research symposium, and various collaborative ?Innovation Groups?, which transcend departmental boundaries. The Innovation Groups were developed with the goal of enhancing collaborative interactions and grants, and investigator-initiated clinical trials involving basic, biomedical, population science in concert with clinical experts in six disease sites. Administration orchestrates the goals of these groups. Central operations, fiscal affairs, contract and grant administration, purchasing, event planning, proposal development, public affairs, managing various list serves, communication tools and the Cancer Center Web site (http://cancer.ucdmc.ucdavis.edu) are other core services provided by Cancer Center Administration to the Director, Associate Directors (ADs), senior leaders and to the membership at large to advance strategic plans, new areas of research, and team science. PART II: Senior Leadership oversees the mission of the Center and the formation and implementation of its strategic plan. They work to ensure that beyond delivering the best possible patient care we also generate and disseminate new knowledge. It is the task of leadership to see that the resources available to the Center are optimally utilized to maximize the broadest possible input into the process that is Cancer. As a Comprehensive Cancer Center we are working to increase our transdisciplinary and translational research in order to continually increase our impact within and beyond our catchment area while expanding the scientific scope of the center. Senior Leadership accomplished these goals both through individual contributions in an assigned area and collectively working as a team.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA093373-18
Application #
9993286
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
18
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Braithwaite, Dejana; Miglioretti, Diana L; Zhu, Weiwei et al. (2018) Family History and Breast Cancer Risk Among Older Women in the Breast Cancer Surveillance Consortium Cohort. JAMA Intern Med 178:494-501
Unger, Jakob; Sun, Tianchen; Chen, Yi-Ling et al. (2018) Method for accurate registration of tissue autofluorescence imaging data with corresponding histology: a means for enhanced tumor margin assessment. J Biomed Opt 23:1-11
Wang, Guobao; Corwin, Michael T; Olson, Kristin A et al. (2018) Dynamic PET of human liver inflammation: impact of kinetic modeling with optimization-derived dual-blood input function. Phys Med Biol 63:155004
Winer, Rachel L; Tiro, Jasmin A; Miglioretti, Diana L et al. (2018) Rationale and design of the HOME trial: A pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake and effectiveness in a U.S. healthcare system. Contemp Clin Trials 64:77-87
Withers, Sita S; Skorupski, Katherine A; York, Daniel et al. (2018) Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma. Vet Comp Oncol :
Floc'h, Nicolas; Martin, Matthew J; Riess, Jonathan W et al. (2018) Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. Mol Cancer Ther 17:885-896
Shih, Tsung-Chieh; Liu, Ruiwu; Wu, Chun-Te et al. (2018) Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion. Clin Cancer Res 24:4319-4331
Weiss, Robert H (2018) Metabolomics and Metabolic Reprogramming in Kidney Cancer. Semin Nephrol 38:175-182
Hegde, John V; Shaverdian, Narek; Daly, Megan E et al. (2018) Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial. Cancer 124:521-529
Arun, Adith S; Tepper, Clifford G; Lam, Kit S (2018) Identification of integrin drug targets for 17 solid tumor types. Oncotarget 9:30146-30162

Showing the most recent 10 out of 836 publications